254 related articles for article (PubMed ID: 33227408)
1. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.
de Steur WO; van Amelsfoort RM; Hartgrink HH; Putter H; Meershoek-Klein Kranenbarg E; van Grieken NCT; van Sandick JW; Claassen YHM; Braak JPBM; Jansen EPM; Sikorska K; van Tinteren H; Walraven I; Lind P; Nordsmark M; van Berge Henegouwen MI; van Laarhoven HWM; Cats A; Verheij M; van de Velde CJH;
Ann Oncol; 2021 Mar; 32(3):360-367. PubMed ID: 33227408
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
3. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
Dikken JL; van Sandick JW; Maurits Swellengrebel HA; Lind PA; Putter H; Jansen EP; Boot H; van Grieken NC; van de Velde CJ; Verheij M; Cats A
BMC Cancer; 2011 Aug; 11():329. PubMed ID: 21810227
[TBL] [Abstract][Full Text] [Related]
4. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
[TBL] [Abstract][Full Text] [Related]
5. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
[TBL] [Abstract][Full Text] [Related]
6. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
7. Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma.
Lee TC; Wima K; Morris MC; Johnston ME; Shah SA; Ahmad SA; Patel SH; Wilson GC
J Gastrointest Surg; 2021 Jan; 25(1):36-47. PubMed ID: 33201456
[TBL] [Abstract][Full Text] [Related]
8. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
[TBL] [Abstract][Full Text] [Related]
10. Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer: 5-Year survival data of a randomized controlled trial.
Kairevičė L; Latkauskas T; Tamelis A; Petrauskas A; Paužas H; Žvirblis T; Jaruševičius L; Saladžinskas Ž; Pavalkis D; Jančiauskienė R
Medicina (Kaunas); 2017; 53(3):150-158. PubMed ID: 28690144
[TBL] [Abstract][Full Text] [Related]
11. Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; de Steur WO; Dikken JL; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Kranenbarg WMM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Gastric Cancer; 2019 Mar; 22(2):369-376. PubMed ID: 30238171
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
[TBL] [Abstract][Full Text] [Related]
13. Postoperative adjuvant chemotherapy versus chemoradiotherapy for node-positive esophageal squamous cell carcinoma: a propensity score-matched analysis.
Wang Q; Lang J; Li T; Peng L; Dai W; Jiang Y; Xie T; Fang Q; Wang Y; Wu L; Cao B; Han Y
Radiat Oncol; 2020 May; 15(1):119. PubMed ID: 32448253
[TBL] [Abstract][Full Text] [Related]
14. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
15. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
[TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
[TBL] [Abstract][Full Text] [Related]
17. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
Kilic L; Ordu C; Ekenel M; Yildiz I; Keskin S; Sen F; Gural Z; Asoglu O; Kizir A; Aykan F
Med Oncol; 2013; 30(3):660. PubMed ID: 23877872
[TBL] [Abstract][Full Text] [Related]
19. Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A).
Nomura M; Kato K; Ando N; Ohtsu A; Muro K; Igaki H; Abe T; Takeuchi H; Daiko H; Gotoh M; Kataoka K; Wakabayashi M; Kitagawa Y
Jpn J Clin Oncol; 2017 Jun; 47(6):480-486. PubMed ID: 28334858
[TBL] [Abstract][Full Text] [Related]
20. Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results From the CRITICS Trial.
Claassen YHM; van Amelsfoort RM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Boot H; Trip AK; Jansen EPM; Kranenbarg EM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Ann Surg; 2019 Dec; 270(6):1096-1102. PubMed ID: 29995679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
